GLP-1 Weight Regain After Stopping: What the Withdrawal Trial Shows

"What happens when I stop?" is a question worth answering before you start, not after. The most direct evidence comes from a planned extension of semaglutide's own pivotal trial — participants who stopped the drug and were followed for another year.

The trial: STEP 1's off-treatment extension

STEP 1 randomized 1,961 adults to 68 weeks of once-weekly semaglutide 2.4 mg or placebo, alongside lifestyle intervention. At week 68, the drug and the structured lifestyle program were both stopped, and researchers followed participants for one further year off treatment¹. That design isolates a specific question: not "does the drug work," but "what happens to the result after it's withdrawn."

The numbers

Through week 68, semaglutide produced a mean weight reduction of 17.3%, versus 2.0% on placebo¹. By week 120 — one year after stopping — semaglutide participants had regained 11.6 percentage points of that loss, landing at a net 5.6% below their original baseline weight¹. Read plainly: participants kept roughly a third of their treatment-phase weight loss a year after stopping, and regained about two-thirds of it. Cardiometabolic markers that had improved during treatment moved back toward baseline over the same period, in step with the weight regain¹.

What this does and doesn't tell you

This is one trial, of one molecule (semaglutide, not tirzepatide), following one specific withdrawal pattern — stopping both the drug and the structured lifestyle program at the same time, at week 68. It does not tell you what happens if you taper rather than stop abruptly, continue at a lower maintenance dose, or keep the lifestyle component going without the drug — none of those variations were the design being tested. What it does establish, with real trial-level data behind it: for most participants in this specific protocol, weight loss on semaglutide was not a one-time, permanent change from the drug alone. It behaved the way most obesity treatments do when they stop — the underlying condition tends to reassert itself once treatment ends.

Why this reframes the "how long do I need to take this" question

If regain is the expected pattern rather than the exception, the more useful planning question shifts from "when can I stop" to "is this a long-term treatment for a chronic condition." That is consistent with how the FDA-approved labels for both Wegovy and Zepbound frame their use — chronic weight management, not a fixed course — and it is worth discussing directly with your prescriber before starting rather than discovering after 68 weeks.

Related reading

The full trial-level efficacy and side-effect numbers behind this same drug are in GLP-1 side effects and GLP-1 dosage and titration schedules. If cost is what's driving a decision to stop, best GLP-1 provider by need and the cheapest GLP-1 board are worth checking before treatment ends rather than after.